[go: up one dir, main page]

ES2173683T3 - Inhibidor del radical superoxido. - Google Patents

Inhibidor del radical superoxido.

Info

Publication number
ES2173683T3
ES2173683T3 ES99107493T ES99107493T ES2173683T3 ES 2173683 T3 ES2173683 T3 ES 2173683T3 ES 99107493 T ES99107493 T ES 99107493T ES 99107493 T ES99107493 T ES 99107493T ES 2173683 T3 ES2173683 T3 ES 2173683T3
Authority
ES
Spain
Prior art keywords
group
lower chain
renting
chain
radical inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99107493T
Other languages
English (en)
Inventor
Masatoshi Chihiro
Hajime Komatsu
Michiaki Tominaga
Yoichi Yabuuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2173683T3 publication Critical patent/ES2173683T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN INHIBIDOR DEL RADICAL SUPEROXIDO QUE CONTIENE, COMO INGREDIENTE EFECTIVO, UN DERIVADO DE AZOL REPRESENTADO POR LA FORMULA GENERAL (1), [EN DONDE, R 1 REPRESENTA UN GRUPO FENILO QUE PUEDE TENER 1 A 3 G RUPOS ALCOXI DE CADENA INFERIOR COMO SUSTITUYENTES EN EL CICLO DE FENILO, UN GRUPO FENILO QUE TIENE UN GRUPO ALQUILENDIOXI DE CADENA INFERIOR O SIMILAR; R 2 REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO FENILO, UN ATOMO DE HIDROGENO, UN GRUPO ALCOXICARBONILO DE CADENA INFERIOR, UN GRUPO ALQUILO DE CADENA INFERIOR, UN GRUPO ALQUILAMINO DE CADENA INFERIOR QUE PUEDE TENER UN GRUPO ALQUILO DE CADENA INFERIOR COMO SUSTITUYENTE, UN GRUPO DIHIDROCARBOESTIRILO O SIMILAR; R 3 REPRESENTA UN GRUPO REPRESENTADO POR LA FORMULA, (R 4B REPRESENTA UN GRUPO HIDROXILO, UN GRUPO CARBOXI, UN GRUPO ALQUENILO DE CADENA INFERIOR O UN GRUPO ALQUILO DE CADENA INFERIOR, M REPRESENTA 0, 1 O 2); X REPRESENTA UN ATOMO DE AZUFRE O UN ATOMO DE OXIGENO] O UNA SAL DEL MISMO.
ES99107493T 1990-11-30 1991-11-29 Inhibidor del radical superoxido. Expired - Lifetime ES2173683T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33772790 1990-11-30

Publications (1)

Publication Number Publication Date
ES2173683T3 true ES2173683T3 (es) 2002-10-16

Family

ID=18311399

Family Applications (3)

Application Number Title Priority Date Filing Date
ES99107493T Expired - Lifetime ES2173683T3 (es) 1990-11-30 1991-11-29 Inhibidor del radical superoxido.
ES91920815T Expired - Lifetime ES2144403T3 (es) 1990-11-30 1991-11-29 Derivados de tiazol como inhibidores de oxigeno activo.
ES01112988T Expired - Lifetime ES2245660T3 (es) 1990-11-30 1991-11-29 Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES91920815T Expired - Lifetime ES2144403T3 (es) 1990-11-30 1991-11-29 Derivados de tiazol como inhibidores de oxigeno activo.
ES01112988T Expired - Lifetime ES2245660T3 (es) 1990-11-30 1991-11-29 Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.

Country Status (10)

Country Link
US (4) US5643932A (es)
EP (3) EP0934937B1 (es)
JP (2) JP2829451B2 (es)
KR (2) KR100195433B1 (es)
CA (3) CA2547947C (es)
DE (3) DE69133471T2 (es)
DK (3) DK1130017T3 (es)
ES (3) ES2173683T3 (es)
TW (1) TW311136B (es)
WO (1) WO1992009586A1 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112987A1 (en) * 1992-05-29 1993-12-09 Masatoshi Chihiro Thiazole derivatives
US5639770A (en) * 1992-05-29 1997-06-17 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives
RU2098418C1 (ru) * 1992-09-14 1997-12-10 Яманоути Фармасьютикал Ко., Лтд. Конденсированное производное тиазола или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность агониста 5-нт*003-рецептора на его основе
EP0637588A4 (en) * 1993-01-19 1995-12-13 Shiseido Co Ltd INHIBITOR OF ACTIVE OXYGEN.
WO1995024399A1 (en) * 1994-03-11 1995-09-14 Yamanouchi Pharmaceutical Co., Ltd. 5-ht3 receptor agonist, novel thiazole derivative, and intermediate therefor
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
ATE269336T1 (de) * 1994-12-22 2004-07-15 Ligand Pharm Inc Steroidrezeptor-modulator verbindungen und methoden
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
JP3896552B2 (ja) * 1996-03-25 2007-03-22 大塚製薬株式会社 チアゾール誘導体−金属錯体
WO1998008844A1 (de) * 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
SI0920426T1 (en) * 1996-08-26 2004-04-30 Altana Pharma Ag New thiazole derivatives with phosphodiesterase-inhibiting effect
JP4305668B2 (ja) * 1996-09-30 2009-07-29 大塚製薬株式会社 サイトカイン異常産生又は接着作用の亢進に伴う疾患を予防又は治療するための薬剤
JP4300373B2 (ja) * 1996-09-30 2009-07-22 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
JP4305662B2 (ja) * 1996-09-30 2009-07-29 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
EP0941226A1 (de) * 1996-11-12 1999-09-15 Byk Gulden Lomberg Chemische Fabrik GmbH (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer
DE69720773T2 (de) * 1996-12-23 2004-01-29 Bristol Myers Squibb Pharma Co SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
PT991625E (pt) * 1997-06-19 2005-10-31 Bristol Myers Squibb Pharma Co Inibidores de factor xa com um grupo de especificidade p1 neutro
ZA985251B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Inhibitors of factor Xa with a neutral P1 specificity group.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
DE69821132T2 (de) * 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
BR9908539A (pt) 1998-01-28 2000-12-05 Shionogi & Co Ltda Compostos tricìclicos
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6322449B1 (en) 1998-02-04 2001-11-27 Klitsner Industrial Design, Llc Mechanical interface device
EP1092711A4 (en) 1998-07-01 2002-07-31 Takeda Chemical Industries Ltd RETINOID ASSOCIATED RECEPTOR REGULATORS
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
CN1585639A (zh) * 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
JP4336913B2 (ja) * 1999-02-12 2009-09-30 大塚製薬株式会社 アミド誘導体の製造方法
JP2000281664A (ja) * 1999-03-30 2000-10-10 Otsuka Pharmaceut Co Ltd チアゾール誘導体
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
ATE312820T1 (de) * 1999-10-28 2005-12-15 Trine Pharmaceuticals Inc Pumpeninhibitoren zur freisetzung von medikamenten
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
EA007464B1 (ru) * 2000-10-02 2006-10-27 Янссен Фармацевтика Н.В. Антагонисты метаботропных рецепторов глутамата
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 3−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
DE10102084B4 (de) 2001-01-18 2006-06-29 Wella Ag 1,4-Diamino-2-(thiazol-2-yl)-benzol-Derivate enthaltende Haarfärbemittel
CA2445697A1 (en) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
DE60206391T2 (de) 2001-07-24 2006-07-13 Otsuka Pharmaceutical Co., Ltd. Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
FR2835254B1 (fr) * 2002-01-25 2006-04-07 Sod Conseils Rech Applic Derives de thiazoles dans le traitement de maladies neurologiques
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AU2003291613B2 (en) * 2002-04-30 2007-09-27 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP2005530800A (ja) * 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
TW200503700A (en) * 2003-07-17 2005-02-01 Otsuka Pharma Co Ltd Enema preparation
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
KR101242310B1 (ko) * 2004-05-17 2013-03-12 오츠카 세이야쿠 가부시키가이샤 티아졸 화합물 및 그의 용도
PL1866296T3 (pl) 2005-04-04 2017-05-31 University Of Florida Research Foundation, Inc. Polieterowe analogi desferritiocyny
EP1932833B1 (en) * 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP2009523701A (ja) * 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉(tetomilast)晶體
TW200815054A (en) 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
RS53084B (sr) 2006-07-05 2014-06-30 Takeda Gmbh Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4, kao što je roflumilast, roflumilast-n-oksid za lečenje inflamatornih plućnih obolenja
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
CA2677264C (en) 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
CA2680592C (en) * 2007-03-15 2016-07-05 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
KR101597665B1 (ko) 2007-08-13 2016-02-24 몬산토 테크놀로지 엘엘씨 선충류 방제용 조성물 및 방법
US8299106B2 (en) * 2007-09-06 2012-10-30 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
HUE060249T2 (hu) * 2008-06-16 2023-02-28 Univ Tennessee Res Found Vegyületek rák kezelésére
JP2012501334A (ja) * 2008-08-29 2012-01-19 トランス テック ファーマ,インコーポレイテッド 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
WO2010043000A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP6054379B2 (ja) * 2011-06-07 2016-12-27 クレベクセル・ファーマClevexel Pharma キナーゼをモジュレートするための組成物および方法
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
US9550764B2 (en) * 2012-08-23 2017-01-24 The Institute Of Cancer Research: Royal Cancer Hospital Fused heterocyclic compounds and their use
US9701638B2 (en) * 2012-11-09 2017-07-11 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
CA2904338C (en) 2013-03-05 2022-07-05 University Of Tennessee Research Foundation Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer
WO2014158942A1 (en) * 2013-03-13 2014-10-02 Avon Products, Inc Compositions for improving the appearance of skin
CN107074839A (zh) * 2013-08-29 2017-08-18 贝勒医学院 用于治疗代谢和体重相关的病症的组合物和方法
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
MX386624B (es) * 2014-12-19 2025-03-19 Galderma Res & Dev Nuevos compuestos, su procedimiento de síntesis y su uso en medicina, así como cosmética.
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
CN116507607A (zh) * 2020-09-25 2023-07-28 神经孔疗法股份有限公司 作为tlr信号传导调节剂的化合物和组合物
EP4291307A4 (en) * 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
KR20240118600A (ko) 2023-01-27 2024-08-05 이택종 분자수소를 유효성분으로 함유하는 항산화 건강보조식품

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1970656A (en) * 1931-11-04 1934-08-21 Winthrop Chem Co Inc Thiazole compound and process of producing the same
BE623714A (es) * 1961-10-19
JPS3910130B1 (es) * 1962-05-10 1964-06-10
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3401120A (en) * 1965-10-23 1968-09-10 Gaf Corp Corrosion inhibitors
GB1139940A (en) * 1966-09-30 1969-01-15 Ici Ltd Oxazole derivatives
DE1670383A1 (de) * 1966-09-14 1970-10-29 Ciba Geigy Neue Tetrahydroimidazole und Verfahren zu ihrer Herstellung
US3462448A (en) * 1966-10-27 1969-08-19 Dow Chemical Co Substituted phenyl thiazole compounds
IL28803A (en) * 1966-11-18 1974-05-16 Wyeth John & Brother Ltd Oxazole and thiazole compounds,their preparation and pharmaceutical compositions containing them
GB1226548A (es) * 1967-06-14 1971-03-31 Wyeth John & Brother Ltd
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3625999A (en) * 1968-02-19 1971-12-07 Lever Brothers Ltd Process for the preparation of phosphonium sulfonate salts
FR96117E (fr) * 1968-03-28 1972-05-19 Aquitaine Petrole Synthese d'oxazoles.
CY800A (en) * 1968-04-09 1976-12-01 Wyeth John & Brother Ltd Novel thiazoline derivatives, the preparation thereof and compositions containing the same
GB1248070A (en) * 1968-12-16 1971-09-29 Science Union & Cie Thiazolyl-benzoic acid derivatives and process for preparing them
US4001420A (en) * 1968-12-12 1977-01-04 Science Union Et Cie, Societe Francaise De Recherche Medical Thiazolyl benzoic acid compounds
US3635999A (en) 1969-03-25 1972-01-18 Aquitaine Petrole Synthesis of oxazoles
US3705153A (en) * 1969-05-14 1972-12-05 Sumitomo Chemical Co Novel thiazolyacetic acids and salts thereof
JPS4637822B1 (es) * 1969-05-31 1971-11-08
JPS4624696B1 (es) * 1969-06-30 1971-07-15
FR2082164A5 (en) * 1970-03-05 1971-12-10 Aries Robert Phenylalkyl esters of oxazolyl and thiazolyl carboxylic - acids - analgesics, antiinflammatories, tranquilisers
GB1308028A (en) * 1970-06-12 1973-02-21 Science Union & Cie Thiazolylbenzoic acid derivatives and a process for their manufactur
DE2048272C3 (de) * 1970-10-01 1974-10-17 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von 1,1,2-Trimethoxyäthanund o-Essigsäuremethylester
CA962269A (en) 1971-05-05 1975-02-04 Robert E. Grahame (Jr.) Thiazoles, and their use as insecticides
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
JPS471469A (es) * 1971-06-22 1972-01-25
DE2152367C2 (de) * 1971-10-21 1985-01-03 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 4- Methyl-oxazolen
BE791087A (fr) * 1971-11-15 1973-03-01 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
BE794096A (fr) * 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
JPS4938268A (es) * 1972-08-16 1974-04-09
JPS4938267A (es) * 1972-08-18 1974-04-09
JPS5327586B2 (es) * 1972-08-23 1978-08-09
JPS503315A (es) * 1973-05-10 1975-01-14
US4072689A (en) * 1973-02-22 1978-02-07 Gruppo Lepetit S.P.A. Monoamino 2,4,5-trisubstituted oxazoles
JPS5030619A (es) * 1973-07-23 1975-03-26
HU168036B (es) * 1973-11-09 1976-02-28
DE2711655A1 (de) * 1977-03-17 1978-09-21 Basf Ag Pyridinyl-aminoalkylaether
US4259341A (en) * 1977-06-01 1981-03-31 Merck & Co., Inc. Di- and tri-substituted thiazoles
US4153703A (en) * 1977-06-30 1979-05-08 Uniroyal, Inc. Method of controlling insects and acarids with certain aryl-substituted thiazoles
JPS5461936A (en) * 1977-10-26 1979-05-18 Ricoh Co Ltd Photoreceptor for electrophotography
JPS6051475B2 (ja) * 1977-11-08 1985-11-14 久光製薬株式会社 新規なフエニル酢酸誘導体
GB1574583A (en) * 1978-02-09 1980-09-10 Wyeth John & Brother Ltd Process for preparing thiazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4221584A (en) * 1979-02-09 1980-09-09 Chevron Research Company Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
JPS55111418A (en) * 1979-02-21 1980-08-28 Santen Pharmaceut Co Ltd Remedy for eye disease and its preparation
NZ193011A (en) * 1979-03-19 1983-03-15 Ici Australia Ltd Diarylamine derivatives intermediates herbicidal compositions
AU534093B2 (en) * 1979-03-19 1984-01-05 Ici Australia Limited Thiazoles,benzthiazoles, benzoxazoles and benzimidazoles
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
US4298743A (en) * 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
JPS56123544A (en) * 1980-03-03 1981-09-28 Hitachi Ltd Composite type electrophotographic plate and electrophotographic method using it
US4322428A (en) * 1980-04-02 1982-03-30 Eli Lilly And Company 2(4-Fluorophenyl)-4,5,-bis(4-methoxyphenyl)thiazole and method of use
ZA811691B (en) * 1980-04-03 1982-10-27 Wyeth John & Brother Ltd Thiazoles
US4329459A (en) * 1980-05-05 1982-05-11 The Upjohn Company Tetrahydrobenzopyran derivatives
US4282364A (en) * 1980-05-22 1981-08-04 Merck & Co., Inc. Process for the preparation of thiazoles
JPS58120257A (ja) * 1982-01-12 1983-07-18 Hitachi Chem Co Ltd 電子写真感光体
DD204094A1 (de) * 1982-02-11 1983-11-16 Horst Hartmann Verfahren zur herstellung von 2-aryl-4-cumaryl-(3')- bzw. 2,4-bis-cumaryl-(3')-thiazolen
JPS58201771A (ja) * 1982-05-19 1983-11-24 Tanabe Seiyaku Co Ltd アルキルオキサゾリル酢酸誘導体
JPS58219169A (ja) * 1982-06-15 1983-12-20 Takeda Chem Ind Ltd オキサゾ−ル酢酸誘導体
JPS5925381A (ja) * 1982-06-30 1984-02-09 Hisamitsu Pharmaceut Co Inc 新規なフエニル酢酸誘導体
JPS5925380A (ja) * 1982-06-30 1984-02-09 Hisamitsu Pharmaceut Co Inc 新規なフエニル酢酸誘導体
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
JPS6051111A (ja) * 1983-08-30 1985-03-22 Tanabe Seiyaku Co Ltd 抗脂血剤
JPS60151045A (ja) * 1984-01-19 1985-08-08 富士写真フイルム株式会社 感光材料用包装材料
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS60222481A (ja) * 1984-04-19 1985-11-07 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
JPS61200985A (ja) * 1985-02-28 1986-09-05 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
US4659726A (en) * 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
JPS6133186A (ja) * 1984-07-25 1986-02-17 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
JPS60230147A (ja) * 1984-04-27 1985-11-15 Ricoh Co Ltd 電子写真製版用印刷原版
DE3425118A1 (de) * 1984-07-07 1986-01-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
JPS6123790A (ja) * 1984-07-12 1986-02-01 Hitachi Cable Ltd NiまたはNi合金表面へのメツキ方法
DE3501696A1 (de) * 1985-01-19 1986-07-24 Bayer Ag, 5090 Leverkusen Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3525689C1 (de) * 1985-07-18 1986-10-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren und Einrichtung zum Betrieb eines mit einer Protonenuebertragungsreaktion arbeitenden Farbstoff-Lasers
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
DE3601411A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 3-amino-1-(2-thiazolyl)-2-pyrazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
KR900000566B1 (ko) * 1986-04-30 1990-01-31 에프 엠 씨 코포레이션 광활성 아졸 살충제
JPH075579B2 (ja) * 1986-09-01 1995-01-25 吉富製薬株式会社 アミノチアゾ−ル化合物
JPS63192755A (ja) * 1987-02-06 1988-08-10 Fujisawa Pharmaceut Co Ltd 2−フエニルアゾ−ル誘導体およびその塩
US4791200A (en) * 1987-06-22 1988-12-13 Ortho Pharmaceutical Corporation 2-substituted-4-aryl-substituted thiazoles
JPS6422861A (en) * 1987-07-18 1989-01-25 Kirin Brewery New substance ag55-2
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
JPH02171280A (ja) * 1988-12-26 1990-07-02 Agency Of Ind Science & Technol インクジェット用蛍光性インク組成物
DE3929233A1 (de) 1989-09-02 1991-03-07 Bayer Ag 5-heterocyclyl-pyridin-3-carbon-benzylamide und -anilide
AU621245B2 (en) * 1989-10-17 1992-03-05 Boehringer Mannheim Gmbh Hydrolase substrates, a process for the preparation thereof and agents containing them

Also Published As

Publication number Publication date
TW311136B (es) 1997-07-21
US5643932A (en) 1997-07-01
CA2547947C (en) 2007-09-25
CA2396738A1 (en) 1992-06-25
AU8936791A (en) 1992-06-25
ES2144403T3 (es) 2000-06-16
EP0513387A4 (en) 1993-04-21
KR927003551A (ko) 1992-12-18
HK1003938A1 (en) 1998-11-13
CA2074933A1 (en) 1992-05-31
JPH10101562A (ja) 1998-04-21
WO1992009586A1 (en) 1992-06-11
EP0513387A1 (en) 1992-11-19
CA2547947A1 (en) 1992-06-25
DE69133471D1 (de) 2005-07-21
EP0934937A1 (en) 1999-08-11
US5677319A (en) 1997-10-14
DE69132944T2 (de) 2002-11-21
EP1130017B1 (en) 2005-06-15
CA2074933C (en) 2002-12-03
DE69132006D1 (de) 2000-04-06
ES2245660T3 (es) 2006-01-16
EP0934937B1 (en) 2002-02-27
DE69132006T2 (de) 2000-08-03
DE69133471T2 (de) 2006-05-11
DK0934937T3 (da) 2002-04-02
JPH0551318A (ja) 1993-03-02
CA2396738C (en) 2006-08-29
EP1130017A2 (en) 2001-09-05
JP2829451B2 (ja) 1998-11-25
EP0513387B1 (en) 2000-03-01
DK0513387T3 (da) 2000-06-05
AU656930B2 (en) 1995-02-23
JP3182556B2 (ja) 2001-07-03
DK1130017T3 (da) 2005-10-10
KR100249545B1 (en) 2000-04-01
USRE37556E1 (en) 2002-02-19
US6080764A (en) 2000-06-27
KR100195433B1 (ko) 1999-06-15
EP1130017A3 (en) 2001-09-19
DE69132944D1 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
ES2173683T3 (es) Inhibidor del radical superoxido.
ES2030777T3 (es) Un metodo para preparar un derivado de n-indanil-carboxamida, y fungicida agricola/horticola que contiene el derivado como ingrediente activo.
DK0631575T3 (da) Substituerede pyrimidiner samt deres anvendelse som fungicider
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
NO874549D0 (no) Sulfonperoxycarboxylsyrer, deres anvendelse for blekning og preparater inneholdende samme.
ES2051843T3 (es) Un proceso para la preparacion de un derivado del acido benzoilaminofenoxibutanico.
ES2040366T3 (es) Procedimiento de preparacion de nuevos derivados de 1-(bencilpiperidino)2-propanol.
MX9100607A (es) Compuesto triciclico novedoso o sales del mismo,metodo para producir el mismo y agente antimicrobiano que lo contiene
ATE66675T1 (de) Stickstoffhaltige heterozyklische verbindungen.
ES2052539T3 (es) Procedimiento para preparar isoxazolidinas 2,3-disustituidas.
EP0654266A4 (en) HEART PROTECTIVE.
DE3580132D1 (de) Aromatische verbindungen.
ES2058209T3 (es) Derivados amidicos, procedimiento para su produccion y fungicidas agricola-horticolas que los contienen.
FI923033A0 (fi) N-fenyltioureaderivat och farmaceutisk anvaendning av dem.
ES2070238T3 (es) Emulsion de lipidos que contiene un analogo de prostaglandina.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ES2070379T3 (es) Composiciones herbicidas.
CO4520266A1 (es) Derivado de 1,3-oxazin-4-ona, el herbicida que lo contiene y los productos intermedios para prepararlo
DE3067006D1 (en) Insecticides and piperidine derivative
ES2119874T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2052009T3 (es) Compuestos ciclicos que contienen azufre.
ES2196001T3 (es) Derivado de pirroloazepina.
ES2090374T3 (es) Derivados de tiazolina, procesos para su preparacion y composiciones plaguicidas que los contienen.
ES2053629T3 (es) Resinas de bismaleinimida.
ATE125190T1 (de) Zusammensetzung zur holzkonservierung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 934937

Country of ref document: ES